| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.6M | — | -12.1% |
| SG&A Expense | $2.7M | — | -1.3% |
| Operating Income | -$5.1M | — | +8.3% |
| Net Income | -$5.1M | — | +8.3% |
| EPS (Basic) | -$0.26 | — | -271.4% |
| EPS (Diluted) | -$0.26 | — | -271.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Current Assets | $22.7M | -18.7% | +78.1% |
| Total Assets | $26.3M | -18.6% | +32.2% |
| Current Liabilities | $2.2M | -31.7% | -27.0% |
| Total Liabilities | $3.5M | -26.2% | -41.9% |
| Stockholders' Equity | $22.8M | -17.3% | +64.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.9M | — | -58.5% |
| Investing Cash Flow | -$9K | — | — |
| Financing Cash Flow | -$195K | — | -105.0% |